Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best single digit stocks to buy according to analysts. On January 8, Morgan Stanley lowered its price target for Rocket Pharmaceuticals from $7 to $5 while keeping an Equal Weight rating. In a 2026 group outlook, the firm noted it expects continued outperformance for US small-to-mid cap biotech as commercial companies shift from consuming capital to producing it, while large-cap biopharma faces an approaching patent cliff.

In Q3 2025, Rocket Pharmaceuticals achieved significant regulatory and clinical milestones, including the FDA lifting the clinical hold on its Phase 2 pivotal trial of RP-A501 for Danon disease, which is scheduled to resume dosing in H1 2026. Additionally, the FDA set a PDUFA action date of March 28 this year for KRESLADI, which is a gene therapy for severe LAD-I, marking a critical move toward the company’s first potential commercial launch.

While advancing its cardiovascular portfolio with RP-A601 and RP-A701, Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) remains focused on its hematology programs and the potential receipt of a Rare Pediatric Disease Priority Review Voucher upon the anticipated approval of KRESLADI.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT), together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.